John Oyler - BGNE Old Chairman of the Board, CEO, Founder
Chairman
Mr. John Victor Oyler is Executive Chairman of the Board, Chief Executive Officer of the Company. He has served as a member of our Board since October 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corporationration, a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1998 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was bought by The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as CoChief Executive Officer of Genta Incorporated, an oncologyfocused biopharmaceutical company listed on the Nasdaq under ticker symbol GNTA. Mr. Oyler began his career as a management consultant at McKinsey Company since 2010.
| Age | 57 |
| Tenure | 15 years |
| Professional Marks | MBA |
| Phone | 345-949-4123 |
| Web | https://www.beigene.com |
John Oyler Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Oyler against BGNE Old stock is an integral part of due diligence when investing in BGNE Old. John Oyler insider activity provides valuable insight into whether BGNE Old is net buyers or sellers over its current business cycle. Note, BGNE Old insiders must abide by specific rules, including filing SEC forms every time they buy or sell BGNE Old'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Oyler over three months ago Disposition of 428 shares by John Oyler of BeiGene at 234.2728 subject to Rule 16b-3 | ||
John Oyler over three months ago Disposition of 1452 shares by John Oyler of BeiGene at 236.3695 subject to Rule 16b-3 | ||
John Oyler over six months ago Disposition of tradable shares by John Oyler of BeiGene at 150.85 subject to Rule 16b-3 | ||
John Oyler over six months ago Disposition of 7924 shares by John Oyler of BeiGene at 154.2084 subject to Rule 16b-3 |
BGNE Old Management Efficiency
The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BGNE Old's management efficiency ratios could be used to measure how well BGNE Old manages its routine affairs as well as how well it operates its assets and liabilities.BGNE Old currently holds 930.18 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. BGNE Old has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BGNE Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Herve Hoppenot | Incyte | 65 | |
| Stanley Crooke | Ionis Pharmaceuticals | 79 | |
Management Performance
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 |
BGNE Old Leadership Team
Elected by the shareholders, the BGNE Old's board of directors comprises two types of representatives: BGNE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGNE. The board's role is to monitor BGNE Old's management team and ensure that shareholders' interests are well served. BGNE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BGNE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, CoChairman CoFounder | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Chan Lee, General VP | ||
| Wang Lai, Global RD | ||
| Kevin Mannix, VP Relations | ||
| Titus Ball, VP Officer | ||
| Julia Wang, Executive Officer | ||
| Aaron Rosenberg, CFO Officer | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Daniel Maller, VP Accounting | ||
| Jaspreet MD, Senior Strategy | ||
| Diana Francis, VP Compliance | ||
| Melika Davis, Clinical Head | ||
| Yan Qi, Senior China | ||
| Xiaobin Wu, President COO |
BGNE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BGNE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.14) % | |||
| Current Valuation | 18.78 B | |||
| Shares Outstanding | 97.63 M | |||
| Shares Owned By Insiders | 19.43 % | |||
| Shares Owned By Institutions | 46.90 % | |||
| Number Of Shares Shorted | 1.38 M | |||
| Price To Earning | (16.19) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in BGNE Stock
If you are still planning to invest in BGNE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BGNE Old's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |